4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a definitive agreement for a $6.0 million Series C Preferred Stock investment with The Patel Family, LLP. The shares of Series C Preferred Stock will have a 7.5% dividend per year, accruing and payable quarterly. The Series C Preferred Stock is convertible into shares of common stock after 6 months at the election of the holder, and callable by Tevogen for redemption after 5 years at Tevogen's e

WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ending June 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. Tevogen's reported $5.1 million net cash used in operating activities and $33.0 million in non-cash expenses for the six months ending June 30, 2024. The key non-cash expense items included $30.5 million in stock-based compensation expenses. The Com

The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.Pioneering the Economics of Health to examine the interdependencies of the healthcare ecosystem which are often overlooked when only considering a singular silo of it.AI In Biopharma to highlight how AI-driven technologies can revolutionize drug discovery, accelerate development timelines, enhance patient accessibility, foster quicker innovation, and significantly reduce operating costs.Panelists to include David Rhew (Global Chief Medica

WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today the company will host an AI panel during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The panel, titled "AI in Biopharma: Next Frontier of Medical Innovation," will explore the transformative potential of artificial intelligence in the biopharma industry. Panelists will include Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare of Microsoft (NASDAQ:MSFT),

WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, filed for an additional patent, "Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models", as part of its developing intellectual property portfolio. In October 2023, Tevogen Bio launched its artificial intelligence effort, Tevogen.AI with the explicit goal to expedite enhancement of drug discovery, development, manufacturing, distribution, and patient access not only for T

WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it will host a compelling panel discussion, "Pioneering the Economics of Health: Balancing Access and Outcomes," during the 43rd Annual J.P. Morgan Healthcare Conference. This panel will bring together global thought leaders to examine the critical interdependencies of the healthcare ecosystem, a dynamic interplay between patient accessibility, medical innovation, reimbursement mechanism and heal

WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced that Founder and CEO Ryan Saadi, MD, MPH, will be attending the J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco, CA. The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together key stakeholders to discuss innovations and advancements in the sector. For inquiries about Tevogen Bio's JP Morgan even

WARREN, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, CEO of Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, congratulates Board Member, Victor Sordillo PE, CSP, MBA, as he was inducted into The New Jersey League of Municipalities Hall of Fame this month. Mayor Sordillo was inducted into the Hall of Fame for his dedicated tenure of 24 years of continuous service as a Warren Township Committee Member. As an elected official, Mayor Sordillo served the community by leading the municipal government, pro

WARREN, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced addition responsibilities for key leaders to further expand company capabilities. As part of this leadership evolution: Tapan V Shah, Head of Investor Relations and Corporate Development, will take on added responsibility for US Government Affairs and Policy.William Keane, Vice President of Strategic Initiatives, will assume additional responsibilities for New Business Development.Wojtek Stobinsk

WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company's determination to advance its mission of developing accessible, life-saving therapeutics. The company recently announced significant progress through its third quarter financial results for 2024, including, reduction of a net loss by $52.5 million, elimination of nearly

Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.8 million for the nine months ended September 30, for 2024 and 2023, respectively.Significantly improved financial position by eliminating nearly all of its liabilities; reported $10.5 million as of September 30, 2024, and $99.9 million as of December 31, 2023.$10 billion+, representing Tevogen's IP and product assets based on internal discounted cash flow models, is not reflected on the company balance sheet. Similarly, Tevogen's AI assets, a critical component of its innovation platform, remain unreported on company balance sheet.Sufficient available capital to fund operations fo

Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm.Tevogen's success would not be possible without its passionate team united by a common vision.Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution.Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price of $11.50 per share which could provide the company with over $200 million. WARREN, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NAS

WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, is pleased to announce the appointment of Anthony Tarantino as its new Patient Advocate. Tarantino, a well-known leader in firefighter safety and community advocacy, brings extensive experience in representing and supporting high-risk groups, including first responders. Anthony Tarantino previously served as President of the Newark Fire Officers Union and Legislative Vice President of the Professional Firefighters As

WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio ("Tevogen") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Salesforce CEO Marc Benioff on receiving the Yale Legend in Leadership Award for highlighting that business success must coexist with social prosperity at the bi-annual CEO Summit. The Yale Legend in Leadership Award was created 35 years ago to honor current and former CEOs who serve as living legends to inspire chief executives across industries, sectors, and nations. "I share Marc's belief

WARREN, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membershi

WARREN, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, announces the appointment of William Keane as Vice President of Strategic Initiatives. Mr. Keane brings 35 years of leadership experience in law enforcement, having most recently served as the Chief of Police for Warren, New Jersey, for the past decade. He has also held various management positions throughout his career. He will work closely with various functional leads to ensure policies and procedures conform

WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio') (NASDAQ:TVGN), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of Investor Relations and Corporate Development. Mr. Shah, a Wall Street veteran with over 25 years of experience across key financial services industry verticals, brings broad leadership capabilities to Tevogen Bio. Most recently, Mr. Shah was Director, Relationship Management, in Citigroup's Client organization, where he was also a member of the Executive Office. Prior to Citigroup, he worked in Morgan Stanley's asset management business (MSIM) focused on Equity Strategy and Product Development. Mr.

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

10-Q - Tevogen Bio Holdings Inc. (0001860871) (Filer)

NT 10-Q - Tevogen Bio Holdings Inc. (0001860871) (Filer)

424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

8-K/A - Tevogen Bio Holdings Inc. (0001860871) (Filer)

424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

10-Q - Tevogen Bio Holdings Inc. (0001860871) (Filer)

424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)